Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Savient

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Ironwood claims FDA OK for former AZ gout drug

Duzallo will be launched in the US before the end of this year

AstraZeneca AZ

AZ sells Zurampic rights to Gruenenthal for $230m

Continues to sell off unwanted assets in order to focus resources and meet $45bn sales target

AstraZeneca AZ

AZ adds gout drug Zurampic to asset sale

Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product

- PMLiVE

AZ moves a step closer to gout drug approval in US

Final verdict to be delivered in end of December

- PMLiVE

AZ’s phase III gout data frustrates firm

Lesinurad discrepancies highlighted in clinical trials

- PMLiVE

AZ files gout drug lesinurad in Europe

Acquired drug as part of its takeover of Ardea Biosciences in 2012

- PMLiVE

Phase III data back AZ’s gout drug

Lesinurad on course to be filed this year

- PMLiVE

Good news for AZ on gout candidate lesinurad

Phase III trial backs planned filing in 2014

- PMLiVE

Savient faces bankruptcy after Krystexxa sales disappoint

Agrees sale of assets including the gout drug

- PMLiVE

Novartis and Savient face NICE rejections

Jakavi and Krystexxa turned down for NHS use in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links